Candriam S.C.A. Longboard Pharmaceuticals, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LBPH
# of Institutions
126Shares Held
34.9MCall Options Held
28.9KPut Options Held
13.9K-
Farallon Capital Management LLC San Francisco, CA3.15MShares$189 Million0.53% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.91MShares$174 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.79MShares$167 Million6.52% of portfolio
-
Black Rock Inc. New York, NY2.37MShares$142 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$122 Million0.0% of portfolio
About Longboard Pharmaceuticals, Inc.
- Ticker LBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,586,000
- Market Cap $815M
- Description
- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...